Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Bruijniks, Sanne J. E.; Grootheest, Gerard van; Cuijpers, Pim; Kluiver, Hilde de; Vinkers, Christiaan H.; Peeters, Frenk; Penninx, Brenda W.J.H.; Teunissen, Charlotte E.; Huibers, Marcus J.H.

doi:10.1016/j.jpsychires.2020.07.045

Cited by 19 publications

(15 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a genome-wide meta-analysis did not associate the presence of the Val66Met polymorphism with psychological treatment outcomes for depression (Rayner et al, 2019). Finally, a recent trial evaluating the presence of the Val66Met polymorphism and pretreatment and posttreatment BDNF serum levels for both cognitive behavior therapy and interpersonal therapy in severe MDD patients did not find any significant association with outcomes after 6 months (Bruijniks et al, 2020). These results were not influenced by treatment modality or frequency (once or twice per week) of therapy.…”

Section: Clinical and Treatment Perspectivesmentioning

confidence: 91%

“…This finding can shed some light on the mechanisms by which BDNF may influence psychotherapy results. Cognitive abilities are required in the psychotherapeutic process to reduce depressant stimulants and to cope with negative feelings (Bruijniks et al, 2020). Previously, cognitive domains such as memory performance (Azeredo et al, 2017) and attention (Mikoteit et al, 2015) were associated with BDNF levels, which are mainly expressed in the hippocampus, a region responsible for memory and inter-related cognitive functions in addition to the regulation of stress (Dranovsky and Hen, 2006).…”

Section: Clinical and Treatment Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Arosio

Guerini

Voshaar

et al. 2021

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Major depressive disorder (MDD) affects millions of people worldwide and is a leading cause of disability. Several theories have been proposed to explain its pathological mechanisms, and the “neurotrophin hypothesis of depression” involves one of the most relevant pathways. Brain-derived neurotrophic factor (BDNF) is an important neurotrophin, and it has been extensively investigated in both experimental models and clinical studies of MDD. Robust empirical findings have indicated an association between increased BDNF gene expression and peripheral concentration with improved neuronal plasticity and neurogenesis. Additionally, several studies have indicated the blunt expression of BDNF in carriers of the Val66Met gene polymorphism and lower blood BDNF (serum or plasma) levels in depressed individuals. Clinical trials have yielded mixed results with different treatment options, peripheral blood BDNF measurement techniques, and time of observation. Previous meta-analyses of MDD treatment have indicated that antidepressants and electroconvulsive therapy showed higher levels of blood BDNF after treatment but not with physical exercise, psychotherapy, or direct current stimulation. Moreover, the rapid-acting antidepressant ketamine has presented an early increase in blood BDNF concentration. Although evidence has pointed to increased levels of BDNF after antidepressant therapy, several factors, such as heterogeneous results, low sample size, publication bias, and different BDNF measurements (serum or plasma), pose a challenge in the interpretation of the relation between peripheral blood BDNF and MDD. These potential gaps in the literature have not been properly addressed in previous narrative reviews. In this review, current evidence regarding BDNF function, genetics and epigenetics, expression, and results from clinical trials is summarized, putting the literature into a translational perspective on MDD. In general, blood BDNF cannot be recommended for use as a biomarker in clinical practice. Moreover, future studies should expand the evidence with larger samples, use the serum or serum: whole blood concentration of BDNF as a more accurate measure of peripheral BDNF, and compare its change upon different treatment modalities of MDD.

show abstract

Section: Clinical and Treatment Perspectivesmentioning

confidence: 91%

Section: Clinical and Treatment Perspectivesmentioning

confidence: 99%

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Arosio

Guerini

Voshaar

et al. 2021

Front. Behav. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Bruijniks et al [ 53 ] analyzed changes in serum BDNF concentration levels in a randomized trial that investigated the effects of session frequency on outcomes in cognitive behavioral therapy and interpersonal psychotherapy for depression. They found no change in BDNF levels after psychotherapy, regardless of therapy type or session frequency.…”

Section: Resultsmentioning

confidence: 99%

The Influence of Psychotherapy on Peripheral Brain-Derived Neurotrophic Factor Concentration Levels and Gene Methylation Status: A Systematic Review

Piotrkowicz

Janoska-Jaździk

Koweszko

et al. 2021

JCM

View full text Add to dashboard Cite

Psychotherapy is a well-established method of treating many mental disorders. It has been proven that psychotherapy leads to structural and functional changes in the brain; however, knowledge about the molecular and cellular mechanisms of these changes is limited. Neuroplasticity and one of its mediators, brain-derived neurotrophic factor (BDNF), are potential research targets in this field. To define the role of BDNF concentration in serum, or in plasma, and BDNF promoter gene methylation in saliva or leucocytes, in psychotherapy, an extensive literature search was conducted in the PubMed and Web of Science databases. The literature review was conducted based on papers published up until May 2021 that included pre and post psychotherapy measurements of either BDNF concentration levels or promoter gene methylation status. Ten studies were indicated as eligible for analysis: eight studies that investigated peripheral BDNF concentration levels, one study that investigated methylation status, and one study that included an evaluation of both subject matters. Patients underwent cognitive behavioral therapy or interpersonal psychotherapy. Patients were diagnosed with borderline personality disorder, major depressive disorder, anorexia nervosa, bulimia nervosa, or post-traumatic stress disorder. There were only three of the nine studies that showed statistically significant increases in BDNF concentration levels after psychotherapy. The two studies that involved BDNF gene methylation status showed a decrease in methylation after dialectical behavioral therapy of borderline patients.

show abstract

“…Based on in vivo studies, it has been proved that the mechanism of action of antioxidants is related to the modulation of cell signaling pathways associated with cognitive processes; stimulation of synaptic plasticity; participation in the expression of genes encoding antioxidant enzymes, and neurotrophic factors; as well as improvement of cerebral circulation [ 32 , 33 , 34 ]. Among the many bioactive phytocompounds described so far, we chose those that have the best documented health-promoting properties in many aspects of health, including, in part, suppressing cognitive disorders and the molecular mechanisms of their action are relatively well understood.…”

Section: In Vivo Studies and Clinical Trials On Improving Cognition By Various Antioxidantsmentioning

confidence: 99%

Unusual Bioactive Compounds with Antioxidant Properties in Adjuvant Therapy Supporting Cognition Impairment in Age-Related Neurodegenerative Disorders

Cichoń

Dziedzic

Gorniak

et al. 2021

IJMS

View full text Add to dashboard Cite

Cognitive function decline is strictly related to age, resulting in the loss of the ability to perform daily behaviors and is a fundamental clinical neurodegeneration symptom. It has been proven that an adequate diet, comprehensive nutrition, and a healthy lifestyle may significantly inhibit neurodegenerative processes, improving cognitive functions. Therefore, intensive research has been conducted on cognitive-enhancing treatment for many years, especially with substances of natural origin. There are several intervention programs aimed at improving cognitive functions in elderly adults. Cognitive functions depend on body weight, food consumed daily, the quality of the intestinal microflora, and the supplements used. The effectiveness in the prevention of dementia is particularly high before the onset of the first symptoms. The impact of diet and nutrition on age-associated cognitive decline is becoming a growing field as a vital factor that may be easily modified, and the effects may be observed on an ongoing basis. The paper presents a review of the latest preclinical and clinical studies on the influence of natural antioxidants on cognitive functions, with particular emphasis on neurodegenerative diseases. Nevertheless, despite the promising research results in animal models, the clinical application of natural compounds will only be possible after solving a few challenges.

show abstract

Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Abstract: Working memory moderates the relation between the brainderived neurotropic factor (BDNF) and psychotherapy outcome for depression.

Cited by 19 publications

References 60 publications

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

The Influence of Psychotherapy on Peripheral Brain-Derived Neurotrophic Factor Concentration Levels and Gene Methylation Status: A Systematic Review

Unusual Bioactive Compounds with Antioxidant Properties in Adjuvant Therapy Supporting Cognition Impairment in Age-Related Neurodegenerative Disorders

Contact Info

Product

Resources

About